Blood Group Genotyping for Sickle Cell and Thalassaemia

NHS England has awarded a contract titled "Blood Group Genotyping for Sickle Cell and Thalassaemia" to NHSBT. This project falls under the health services industry category and is located in London, United Kingdom. The procurement method was a direct award, justified by the absence of competition for technical reasons, as NHSBT is uniquely qualified to deliver this service.

This contract aims to integrate blood group genotyping into routine practices, enhancing the safety and treatment effectiveness for patients with rare blood disorders. The procurement stage is complete, with key dates including the contract period from 19th December 2025 to 31st March 2026 and the award notice published on 5th December 2025. This contract presents an opportunity for businesses specialising in health services technology, particularly those focused on genotyping and rare blood disorders, to engage in partnerships or collaborations with NHS England.

Companies that offer innovative solutions or bespoke health service delivery to meet complex medical requirements may find growth potential by demonstrating technical expertise similar to NHSBT’s capabilities. Although this specific tender was a direct award, understanding the niche expertise required can support businesses aiming to position themselves for future NHS contracts requiring specialised medical services.